New lipid-lowering drugs help patients reduce LDL cholesterol

August 1, 2016

A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels.

Mutations in the gene that encodes PCSK9 (proprotein convertase subtilisin/kexin type 9) have been linked to . PCSK9 causes elevated blood levels of LDL cholesterol because it binds to the LDL receptor. Two anti-PCSK9 antibodies have recently been approved by the US Food and Drug Administration and the European Medicines Agency: alirocumab and evolocumab.

Researchers identified 12 studies of alirocumab and nine of evolocumab, including more than 10,000 patients, most of whom were taking statins but still had elevated cholesterol. All studies demonstrated a reduction in LDL cholesterol with the anti-PCSK9 antibodies. Up to 87% of patients receiving alirocumab and up to 98% receiving evolocumab reached LDL cholesterol goals.

"Both anti-PSCK9 antibodies have cardiovascular outcome studies ongoing with results expected in 2017. We are looking forward to them since it is rather unusual to have results of large outcome trials so soon after the launch of a drug in the market," said Prof. Ioanna Gouni-Berthold, lead author of the British Journal of Clinical Pharmacology study.

Explore further: PCSK9 monoclonal antibodies show promise in ACS

More information: British Journal of Clinical Pharmacology, DOI: 10.1111/bcp.13066

Related Stories

PCSK9 monoclonal antibodies show promise in ACS

March 23, 2016

(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the ...

Statin intolerance objectively identified in patients

April 3, 2016

In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance ...

Recommended for you

Hypertension in young adults shows long-term heart risks

May 19, 2017

Otherwise healthy young people with high systolic blood pressure over 140 are at greater risk for future artery stiffening linked to an increased risk of stroke as well as possible damage to the kidneys and brain, new research ...

Team discovers way to help heart failure patients

May 17, 2017

Shortness of breath is the No.1 complaint of people suffering from heart failure. Now a University of Guelph researcher has discovered its surprising cause - and an effective treatment - in a groundbreaking new study.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.